ProMIS Neurosciences is trading 17.91% up at $15.80 after management reiterated encouraging PMN310 safety and blinded biomarker findings during September 10 conference discussions.
- The six-month interim analysis reported zero ARIA-E cases, zero treatment-related serious adverse events, and no treatment-related dropouts.
- No new September 11 press release was identified; the move appears primarily company-specific, while broader markets were also modestly higher.